Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases
1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort. ...
1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort. ...
Click to read this study in The Lancet Oncology.
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2. ...
Click to read this study in The Lancet Oncology.
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had ...
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had ...
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to ...
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2. ...
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.